Rilotumumab

Research use only, not for human use.

Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling.

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.

Rilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET.Western Blot Analysis Cell Line:U87MG.vIII cells Concentration:10 μg/mL Incubation Time:Overnight Result:Showed MET phosphorylation at tyrosine residue 1234 (Y1234) and Y1235 ~50% lower in U87MG.vIII cells than in untreated cells.Showed an increase in total MET compared with untreated cells.

Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo.Animal Model:6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells Dosage:1.5 mg/kg Administration: Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days Result:Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).

——

Angiogenesis

c-Met/HGFR

c-Met/HGFR

——

——

872514-65-3

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years